Los Angeles Capital Management’s ANI Pharmaceuticals ANIP Stock Holding History

Los Angeles Capital Management’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$186K	Sell	2,247 -19,570	-90%	-$1.57M	﹤0.01%	1192
2026 Q1	$1.68M	Buy	21,817 +967	+5%	+$75.5K	0.01%	543
2025 Q4	$1.92M	Buy	20,850 +1,040	+5%	+$90K	0.01%	456
2025 Q3	$1.81M	Buy	19,810 +5,297	+36%	+$432K	0.01%	531
2025 Q2	$947K	Sell	14,513 -4,410	-23%	-$287K	﹤0.01%	658
2025 Q1	$1.27M	Sell	18,923 -651	-3%	-$38.9K	0.01%	501
2024 Q4	$1.08M	Sell	19,574 -1,900	-9%	-$109K	﹤0.01%	595
2024 Q3	$1.28M	Sell	21,474 -1,500	-7%	-$91.5K	0.01%	562
2024 Q2	$1.46M	Sell	22,974 -2,000	-8%	-$130K	0.01%	527
2024 Q1	$1.73M	Buy	24,974 +5,408	+28%	+$326K	0.01%	535
2023 Q4	$1.08M	Sell	19,566 -129	-0.7%	-$7.1K	﹤0.01%	652
2023 Q3	$1.14M	Sell	19,695 -13,209	-40%	-$762K	﹤0.01%	600
2023 Q2	$1.77M	Buy	+32,904	New	+$1.46M	0.01%	521

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

GACM

Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Los Angeles Capital Management's ANIP Position: Q2 2026 in Review

Los Angeles Capital Management reduced its ANI Pharmaceuticals (ANIP) stake by 90% in Q2 2026, selling an estimated $1.57M and leaving 2,247 shares worth $186K. The position accounts for ﹤0.01% of the portfolio, ranked #1192.

Los Angeles Capital Management first reported a position in ANIP in Q2 2023 and has held it in 13 quarters since. The position peaked at $1.92M in Q4 2025. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

Los Angeles Capital Management held 2,247 shares of ANI Pharmaceuticals worth $186K as of Q2 2026.
Los Angeles Capital Management sold 19,570 ANI Pharmaceuticals shares in Q2 2026, an estimated $1.57M.
ANI Pharmaceuticals made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #1192 holding.
Los Angeles Capital Management first reported a position in ANI Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
Los Angeles Capital Management's ANI Pharmaceuticals position peaked at $1.92M in Q4 2025.
307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.